Alliance of Glycobiologists for Cancer Research: Translational Tumor Glycomics Laboratories (U01)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to continue support for the program referred to as the “Alliance of Glycobiologists for Cancer Research” ( Through this FOA, the NCI encourages research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycan-based abnormalities to serve as biomarkers for early cancer detection or risk assessment. These changes may be studied at the level of glycoproteins, glycolipids, glycosaminoglycans, and/or their binding proteins. In their applications, applicants are encouraged to address the ability of these biomarker candidates to accurately distinguish individuals with cancer from those without. It is expected that the most promising biomarker candidates will ultimately be tested in clinical validation studies, although such validation studies are not required for the proposed projects. All investigators with appropriate expertise and capabilities, irrespective of any prior association with this Alliance, are encouraged to consider applying to this FOA.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): June 8 2017; February 7, 2018; June 8, 2018; February 7, 2019

PAR-17-206 Expiration Date February 8, 2019

Agency Website

Eligibility Requirements

Multiple PD/PI could have different responsibilities with respect to one or more of the following functions: 1) analysis and metrics, 2) medical care interventions, and 3) behavioral interventions.



Amount Description

Application budgets are expected to differ, reflecting the actual needs of the proposed projects. It is anticipated and encouraged, however, that most requests be up to a maximum of $500,000 direct costs per year commensurate with the scope and complexity of the proposed projects.

The total project period may not exceed 5 years.

Funding Type





Medical - Translational

External Deadline

February 7, 2019